Small-Molecule gp120 Cavity Binders for HIV-1 Neutralization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current strategies for preventing HIV-1 transmission and developing effective HIV-1 vaccines face challenges in inhibiting viral entry and eliciting antibodies that recognize conserved elements of the HIV-1 Env trimer, particularly due to the virus's surface variability, conformational lability, and heavy glycosylation, which render existing inhibitors and immunogens less effective.
Innovation Solution
Development of small-molecule compounds that bind to the gp120 cavity, specifically targeting the Phe43 cavity, to sensitize HIV-1 to neutralization by antibodies and enhance the sensitivity of the virus to CD4-induced and V3-directed antibodies, combined with stabilized gp120 core immunogens to elicit protective antibodies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If small-molecule compounds bind to the gp120 cavity to inhibit HIV-1 entry, then viral entry is blocked, but the virus's surface variability and conformational lability reduce inhibitor effectiveness
Solution Approach 1:
The patent targets the highly conserved gp120 cavity region (specifically the Phe43 cavity) which maintains local structural consistency despite overall viral surface variability. By focusing inhibition on this conserved local domain rather than variable surface regions, the compounds achieve reliable binding across different viral strains.
Solution Approach 2:
The small-molecule compounds bind to the gp120 cavity in advance of CD4 receptor interaction, preventing the conformational changes required for viral entry. This preliminary binding blocks the induced-fit mechanism before it can proceed, effectively pre-inhibiting the viral entry pathway.
2Reliability
If stabilized gp120 core immunogens are used to elicit antibodies, then protective immune response is enhanced, but the complexity of vaccine formulation increases
Solution Approach 1:
The stabilized gp120 core structures serve as intermediary immunogens that present conserved epitopes to the immune system in a controlled, stable format. These intermediaries bridge the gap between variable native viral structures and the need for consistent immune recognition, enabling reliable antibody elicitation against conserved regions.
3Strength
If compounds target the conserved gp120-CD4 interface, then binding affinity is improved, but the thermodynamic penalty of molecular ordering reduces binding efficiency
Solution Approach 1:
The patent optimizes compound parameters (molecular structure, flexibility, and binding mode) to achieve favorable binding thermodynamics. By carefully tuning the balance between enthalpic gains from conserved interactions and entropic penalties from molecular ordering, the compounds achieve high binding affinity at the gp120-CD4 interface.
Data Source
AI summary
The disclosure provides compositions and methods for sensitizing primary HIV-1, including transmitted/founder viruses, to neutralization by monoclonal antibodies, e.g., those directed against CD4-induced (CD4i) epitopes and the V3 region. In certain embodiments, the disclosure relates to the use of small molecules as microbicides to inhibit HIV-1 infection directly and to sensitize primary HIV-1 to neutralization by readily elicited antibodies.